Consensus on whether preoperative (pre-op) hyperglycemia predicts adverse surgical outcomes is lacking. The objective of the study was to evaluate the relationship between pre-op HbA1c and postoperative (post-op) surgical outcomes in patients with diabetes mellitus (DM). Patients who underwent bariatric surgery between January 2000 and April 2017 and met the diagnostic criteria of DM and had pre-op HbA1c measures were studied. Logistic and GEE linear regression were used to examine the association between pre-op HbA1c and post-op morbidity and mortality and percentage weight loss (%WL) at 30 days and 1 year. A total of 2173 patients (mean age 48.6 ± 10.6, pre-op weight: 297.5 ± 60.3 lb, 75% females) were evaluated. Among them, 49.6% had HbA1c of < 7%, 26.4% had HbA1c 7-8%, and 23.9% had HbA1c > 8%. The incidence of 30-day complications (readmission, reoperation, bleeding, pulmonary embolism, leak) was 6.1% and 30-day mortality was 0.1%. These rates did not differ between HbA1c groups or between Roux-en-Y gastric bypass (RYGB), sleeve gastrectomy (SG), gastric band, and duodenal switch (DS) procedures. There was no significant association between pre-op HbA1c and complication rates or %WL at 30 days post-op. However, we detected an association between HbA1c and 1-year %WL (p = 0.014) in that 1% increase in pre-op HbA1c was associated with 0.74% less WL at 1 year after adjusting for confounders (95% CI: -1.08% to -0.41%, p < 0.0001). Females lost less weight than males (p = 0.0009) and patients with ≥ 1 anti-hypertensive medications pre-op lost less weight than those without (p < 0.0001) at 1 year. Furthermore, patients operated with DS lost more while those with SG and banding lost less weight than with RYGB.

In conclusion, pre-op HbA1c was not associated with post-op morbidity or mortality but it is a significant predictor for post-op WL at 1 year. Our data suggest that tighter glycemic control pre-op may lead to better weight loss outcomes after bariatric surgery in patients with DM.

Disclosure

C.B. Ortega: None. H. Lee: None. D. Portenier: Consultant; Self; Medtronic, Allergan, Teleflex, Gore, Intuitive. Research Support; Self; Teleflex. A.D. Guerron: Other Relationship; Self; Medtronic, Gore. Consultant; Self; Mederi, Levita. J. Tong: None.

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at http://www.diabetesjournals.org/content/license.